Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05124457

DETERMINE: Detemir vs NPH

A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
336 (estimated)
Sponsor
University of California, Los Angeles · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

Detailed description

Insulin detemir has been used and is FDA approved for type 1 diabetes in pregnancy women and its safety has been well established. At this point, the only long or intermediate acting medication that is approved for type 2 diabetes or gestational diabetes is insulin NPH. The most serious side effect of insulin detemir is hypoglycemia but the rates of hypoglycemia are lower when comparted to NPH both during pregnancy and outside of pregnancy. Diabetes mellitus (DM) is the most common diagnosis in pregnancy and its incidence is continuing to increase. Recent epidemiologic reports place the risk of pre-gestational diabetes at 1-2% and gestational diabetes (GDM) at 12.5%. Risk factors for type 2 diabetes (T2DM) and GDM include obesity, hypertension, family history of diabetes, polycystic ovarian syndrome, or excessive weight gain in pregnancy. Suboptimal control of DM in pregnancy confers significant morbidity on both the mother and fetus, including increased risk of preeclampsia, preterm delivery, perineal lacerations, cesarean delivery, neonatal hypoglycemia, and NICU admissions.

Conditions

Interventions

TypeNameDescription
DRUGInsulin DetemirPatients are to receive insulin detemir
DRUGInsulin NPHPatients are to receive insulin NPH

Timeline

Start date
2022-02-01
Primary completion
2025-06-01
Completion
2025-06-01
First posted
2021-11-18
Last updated
2023-09-26

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05124457. Inclusion in this directory is not an endorsement.